Resilience

PartnerSlate is an online platform that facilitates strategic partnerships for food and beverage brands seeking to bring new products to market. The platform connects these brands with contract manufacturers and other relevant industry partners across North America. By utilizing various criteria, such as location, manufacturing capabilities, and product categories, PartnerSlate streamlines the discovery and connection process. This enables brands to identify and engage with quality production companies, fostering relationships that enhance their manufacturing processes and support their product development goals.

Swiftscale Biologics is a healthcare service provider based in South San Francisco, California, founded in 2019. The company specializes in cell-free protein synthesis, focusing on rapid expression, high-throughput synthesis, and the production of complex proteins. Its innovative platform is designed to test and develop antibodies that inhibit the interaction between viral proteins and human host cells, effectively stopping ongoing coronavirus infections. By advancing these life-saving drugs, Swiftscale Biologics aims to enhance patient outcomes and improve overall health.

Cellevolve Bio is a development and commercialization company specializing in cell therapies aimed at neglected diseases. The company collaborates with innovators to transition early-stage clinical therapies into commercially available treatments, particularly for pediatric and rare diseases. By advancing these therapies into clinical development, Cellevolve aims to significantly enhance patient outcomes and provide expertise in cell therapy and clinical care.

Bit.bio is a synthetic biology company focused on revolutionizing the production and utilization of consistent and functional human cells. Their mission is to enhance health outcomes by applying computational principles to biological processes, specifically through their patented opti-ox™ technology. This innovative approach allows for the reprogramming of human induced pluripotent stem cells into precise and mature cell types. By providing scalable and reliable batches of human cells, Bit.bio aims to improve research, facilitate drug discovery, and foster the development of advanced cell and tissue therapies. The company has assembled a team of experts in stem cells, cellular reprogramming, and mathematical modeling, emphasizing collaboration and ambition to drive their goals forward. Through their efforts, Bit.bio seeks to democratize access to vital cellular resources, ultimately transforming the landscape of medicine.

Garuda Therapeutics is a biotechnology company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening blood, bone marrow, immune, and metabolic diseases. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants. Utilizing advanced technologies, including zebrafish, mice, and human-induced pluripotent stem cells, Garuda Therapeutics conducts research to clone and analyze novel genes and mechanisms critical for blood formation. This innovative approach is designed to provide patients with consistent, durable, and HLA-compatible transgene-free blood stem cell therapies, offering rapid and broad access to life-saving treatments.

Ology Bioservices is an integrated biopharmaceutical company specializing in the development and manufacturing of biopharmaceutical products and medical devices. Founded in 1999 and restructured in 2017, the company operates as a contract development and manufacturing organization (CDMO), providing services that include preclinical and clinical development, formulation optimization, and cGMP manufacturing. Ology Bioservices supports a wide range of drug types, from small molecules to proteins and vaccines, enabling clients to access high-quality biopharmaceutical solutions efficiently and cost-effectively. The company is equipped to manufacture products in compliance with BSL-3 standards, ensuring that it can cater to various client needs within the biopharmaceutical sector.